Statins and cognitive impairment

Grenvil Gracias MSc MD  Scott Garrison MD PhD CCFP  G. Michael Allan MD CCFP

Clinical question
Do statins affect cognitive decline or dementia?

Bottom line
Evidence indicates statins do not prevent, treat, or cause cognitive impairment or dementia. The US Food and Drug Administration warning is based on case reports that might reflect idiosyncratic, short-term, “fuzzy” thinking. Decisions to prescribe statins should not be altered.

Evidence
- A systematic review of 57 studies (19 RCTs, 26 cohort studies, 6 case-control studies, and 6 cross-sectional studies) showed the following:
  - 1 RCT (20 536 patients) showed no effect on incidence of dementia or cognitive impairment.
  - Observational studies reported that statins reduced the incidence. In 10 cohort studies of 4 360 137 patients, the relative risk was 0.87 (95% CI 0.82 to 0.92). Results are unreliable owing to biases (eg, people at lower risk are more likely to use statins).
  - In 18 RCTs (8305 patients) with healthy patients, those with high cholesterol, or those with dementia, overall, 87.7% showed no effect on performance on cognitive function tests, 4.5% improved with statins, and 7.7% improved with placebo. In the largest study (5804 patients), the mean age was 75 years and patients did not have dementia. Patients were followed for 3 years and showed no difference in Mini-Mental State Examination scores.
  - For cognitive adverse events, there was no difference between taking statins and taking clopidogrel or losartan.
  - No effect of statins preventing dementia was seen in a systematic review of 2 RCTs (26 340 patients). Limitations included cognitive function being a secondary outcome.
  - No effect was found in a systematic review of 3 RCTs of statins for treatment of dementia (748 patients with a mean age of 79 years, with probable or possible Alzheimer disease, followed for 6 months or longer). -Trends favour statins preventing cognitive decline. In 1 study, Mini-Mental State Examination scores between those taking statins and those taking placebo were not statistically different (mean difference -1.53 [95% CI -3.28 to 0.21]). However, the results were highly inconsistent.
  - Two systematic reviews found similar results. The adverse reaction might be better described as “fuzzy” or unfocused thinking. It appears to be idiosyncratic and rare, and resolves when the medication is stopped.
  - Lipophilic statins might be more likely to cross the blood-brain barrier and have more central nervous system effects. This is not based on reliable clinical evidence.

Implementation
Statin nonadherence is common. In 1 small sample, 75% did not fill new statin prescriptions within 12 weeks, and half of noncompliers feared side effects. Safety concerns might be missed in RCTs because subjects are healthier, patients with adverse events might be excluded, and adverse events might be superficially explored. Myalgia occurs in 7.5% of placebo and statin RCT patients, but in 10.5% of cohort study patients. Therefore, 10% to 11% of patients might have myalgia but 7.5% of those cases might be unrelated to statins. RxFiles offers a good guide to reintroducing statin therapy in myalgia patients with no or minimal creatine kinase elevation. Patients should be reassured that there are no identified risks of cognitive impairment.

Dr Gracias is a resident at the University of Alberta in Edmonton. Dr Garrison is Associate Professor and Dr Allan is Professor in the Department of Family Medicine at the University of Alberta.

The opinions expressed in Tools for Practice articles are those of the authors and do not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.

References

Tools for Practice articles in Canadian Family Physician (CFP) are adapted from articles published on the Alberta College of Family Physicians (ACFP) website, summarizing medical evidence with a focus on topical issues and practice-modifying information. The ACFP summaries and the series in CFP are coordinated by Dr G. Michael Allan, and the summaries are co-authored by at least 1 practising family physician and are peer reviewed. Feedback is welcome and can be sent to toolsforpractice@cfpc.ca. Archived articles are available on the ACFP website: www.acfp.ca.